- Home
- NRIX vs MQ Comparison
NRIX vs MQ Comparison
Compare NRIX & MQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | MQ |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | 357 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRIX | MQ |
|---|---|---|
| Price | $15.62 | $4.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 10 |
| Target Price | ★ $29.46 | $5.36 |
| AVG Volume (30 Days) | 690.4K | ★ 4.5M |
| Earning Date | 05-01-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $76,987,000.00 | ★ $624,884,000.00 |
| Revenue This Year | N/A | $17.47 |
| Revenue Next Year | $26.32 | $16.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 99.31 | 23.25 |
| 52 Week Low | $8.18 | $3.48 |
| 52 Week High | $22.50 | $7.04 |
Technical Indicators
Market Signals| Indicator | NRIX | MQ |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 44.61 |
| Support Level | $15.62 | $3.83 |
| Resistance Level | $16.47 | $4.46 |
| Average True Range (ATR) | 0.80 | 0.19 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 57.14 | 50.89 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About MQ Marqeta Inc.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.